The Profil Institute for Clinical Research has appointed Dan Bradbury to its board of directors.
Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.
He is currently a managing member of the life sciences consultancy firm BioBrit.
Dr Marcus Hompesch, CEO of diabetes-focused Profil Institute said: “Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry.”
He added: “With Mr Bradbury’s considerable experience in driving strategic growth, I am certain that he will bring tremendous insight and guidance to help further shape the company’s strategic course.”